Autor según el artículo: Piqué, B; Peña, K; Riu, F; Acosta, JC; Torres-Royo, L; Malave, B; Araguas, P; Benavides, R; de Febrer, G; Camps, J; Joven, J; Arenas, M; Parada, D
Departamento: Medicina i Cirurgia
Autor/es de la URV: Arenas Prat, Meritxell / Camps Andreu, Jorge / Febrer Martínez, Gabriel de / Joven Maried, Jorge / Parada Dominguez, David / Peña Gonzalez, Karla Beatriz / Piqué Smith, Berta / Riu Ferrando, Francisco Pedro
Palabras clave: Whole-lung irradiation Viral Rna Prognostic Pneumonia Markers Low-dose radiation therapy Load Covid-19 viral rna prognostic pneumonia markers low-dose radiation therapy load coronavirus
Resumen: Several studies have shown that the plasma RNA of SARS-CoV-2 seems to be associated with a worse prognosis of COVID-19. In the present study, we investigated plasma RNA in COVID-19 patients treated with low-dose radiotherapy to determine its prognostic value. Data were collected from the IPACOVID prospective clinical trial (NCT04380818). The study included 46 patients with COVID-19 pneumonia treated with a whole-lung dose of 0.5 Gy. Clinical follow-up, as well as laboratory variables, and SARS-CoV-2 serum viral load, were analyzed before LDRT, at 24 h, and one week after treatment. The mean age of the patients was 85 years, and none received any of the SARS-CoV-2 vaccine doses. The mortality ratio during the course of treatment was 33%. RT-qPCR showed amplification in 23 patients. Higher mortality rate was associated with detectable viremia. Additionally, C-reactive protein, lactate dehydrogenase, and aspartate aminotransferase were significant risk factors associated with COVID-19 mortality. Our present findings show that detectable SARS-CoV-2 plasma viremia 24 h before LDRT is significantly associated with increased mortality rates post-treatment, thus downsizing the treatment success.
Áreas temáticas: Medicine, general & internal Medicine (miscellaneous) Medicine (all)
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: karlabeatriz.pena@urv.cat david.parada@urv.cat franciscopedro.riu@urv.cat gabrielde.febrer@urv.cat jorge.camps@urv.cat jorge.joven@urv.cat meritxell.arenas@urv.cat berta.pique@estudiants.urv.cat
Identificador del autor: 0000-0002-3165-3640 0000-0003-2749-4541 0000-0003-0815-2570
Fecha de alta del registro: 2024-01-13
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.mdpi.com/2077-0383/12/3/798
URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Journal Of Clinical Medicine. 12 (3):
Referencia de l'ítem segons les normes APA: Piqué, B; Peña, K; Riu, F; Acosta, JC; Torres-Royo, L; Malave, B; Araguas, P; Benavides, R; de Febrer, G; Camps, J; Joven, J; Arenas, M; Parada, D (2023). SARS-CoV-2 Serum Viral Load and Prognostic Markers Proposal for COVID-19 Pneumonia in Low-Dose Radiation Therapy Treated Patients. Journal Of Clinical Medicine, 12(3), -. DOI: 10.3390/jcm12030798
DOI del artículo: 10.3390/jcm12030798
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2023
Tipo de publicación: Journal Publications
Repositori URV